Assessment of the prognostic potential of expression and aberrations in the number of DNA copies of the homological recombination system genes in patients with non-small cell lung cancer

Tsyganov M.M.; Rodionov E.O.; Ibragimova M.K.; Sorokovikova S.S.; Karchevskaya A.A.

doi:10.18137/cardiometry.2023.29.conf.25

SciUp \ Scientific articles \ Applied sciences. Medicine. Technology \ Medical sciences \ Pathology. Clinical medicine \ Communicable diseases. Infectious and contagious diseases, fevers

Assessment of the prognostic potential of expression and aberrations in the number of DNA copies of the homological recombination system genes in patients with non-small cell lung cancer

Tsyganov M.M. Rodionov E.O. Ibragimova M.K. Sorokovikova S.S. Karchevskaya A.A.

Journal: Cardiometry @cardiometry

Section: Conference proceedings

Article in issue: 29, 2023.

Free access

Numerous studies have shown that the presence of homologous recombination deficiency (HRD) in breast tumors may be a good marker of the effectiveness of chemotherapy with DNA-damaging agents such as platinum-based and anthracycline- containing medication regimens. However, the formation of HRD due to disruptions in the BRCA1/2 genes is typical not only for breast cancer and ovarian cancer, but also for other cancer localizations, in particular for non-small cell lung cancer (NSCLC). Since the use of platinum-based drugs in patients with NSCLC is a standard treatment protocol, studying the expression profile of homologous recombination genes and the presence of chromosomal aberrations therein will allow us to fully study HRD in these patients and identify new prognostic markers.

expression \ chromosomal aberrations \ lung cancer \ metastasis-free survival

Similar articles in the section Communicable diseases. Infectious and contagious diseases, fevers

Analysis of Homologous Recombination Deficiency in Prostate Cancer

Iyevleva A.G., Aleksakhina S.N., Sokolenko A.P., Otradnova E.A., Nikitina A.S., Kashko K.A., Syomina M.V., Shestakova A.D., Kuligina E.Sh., Morozova N.S., Imyanitov E.N.

HRD-negative high-grade carcinoma of the ovary in BRCA2 pathogenic variant carrier

Sokolenko A.P., Poletaeva S.V., Shestakova A.D., Gorodnova T.V., Berlev I.V., Imyanitov E.N.

Loss of heterozygosity in the BRCA1 and BRCA2 locus in breast cancer

Tsyganov Matvey M., Ibragimova Marina K., Pevzner Alina M., Litviakov Nikolay V.

Contribution of BRCA1, BRCA2, CHEK2 gene mutations to the pathogenesis of hereditary ovarian cancer in Crimean female patients

Salieva G.M., Golubinskaya E.P., Fomochkina I.I., Kubyshkin A.V.

MRNA expression of chemosensitivity genes as a predictor of response to neoadjuvant chemotherapy in non-small cell lung cancer

Tsyganov Matvey M., Deryusheva Irina V., Rodionov Evgeny O., Efteev Leonid A., Miller Sergey V., Ibragimova Marina K., Perminova Elena E., Cheremisina Olga V., Frolova Irina G., Tuzikov Sergey A., Litviakov Nikolay V.

Radiotherapy in management of BRCA-positiveovarian cancer

Gorodnova Tatiana V., Baranov Sergey B., Tyatkov Tanislav A., Shevkunov Lev N., Sokolenko Anna P., Kotiv Christina B., Imyanitov Evgeny N., Berlev Igor V.

Short address: https://sciup.org/148327397

IDS: 148327397 | DOI: 10.18137/cardiometry.2023.29.conf.25

Text of the article Assessment of the prognostic potential of expression and aberrations in the number of DNA copies of the homological recombination system genes in patients with non-small cell lung cancer

¹Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia
²Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russia
³Tomsk State University, Tomsk, Russia

Introduction . Numerous studies have shown that the presence of homologous recombination deficiency (HRD) in breast tumors may be a good marker of the effectiveness of chemotherapy with DNA-dam-aging agents such as platinum-based and anthra-cycline-containing medication regimens. However, the formation of HRD due to disruptions in the BRCA1/2 genes is typical not only for breast cancer and ovarian cancer, but also for other cancer localizations, in particular for non-small cell lung cancer (NSCLC). Since the use of platinum-based drugs in patients with NSCLC is a standard treatment protocol, studying the expression profile of homologous recombination genes and the presence of chromosomal aberrations therein will allow us to fully study HRD in these patients and identify new prognostic markers.